Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
[b]CPHI Frankfurt
Pluri’s CCO Nimrod Bar Zvi and VP BD Efrat Kaduri will attend the event
https://legacy.pluristem.com/news-and-events/cphi-frankfurt/
PLURI Signs Biologics Collaboration Agreement for Pharma API Development & Manufacturing Today, I am pleased to announce an additional technology collaboration, this time in the biologics industry. Due to a confidentiality agreement with our partner, I can only share limited details at this stage, and we will provide more information once we are able to do so.We have entered a collaboration agreement with one of the world’s leading manufacturers of specialty biologic APIs for liver and gastroenterological diseases. We believe that proof of concept with this agreement and APIs will open opportunities for us to serve additional API manufacturers in the rapidly growing, multi-billion-dollar biologics market.
As part of our collaboration with this major European company, our platform is being utilized to develop and manufacture a unique biologic API used in drugs that treat liver and gastroenterological diseases. The current source of this API is derived from animals that are sacrificed during the extraction process. The joint goal of the collaboration is to grow the specific cells needed for this API in our 3D cell expansion bioreactor systems that are capable of secreting the biological molecule without harming animals. We expect to generate revenues from this collaboration during the coming months. Our cell expansion platform could prove to be a game-changer in the production of biologics, enabling cost-effective, sustainable, and cruelty-free ingredients. Biologic medications, made from live organisms, comprise a rapidly growing industry valued at $366 billion in 2021 and projected to grow to $720 billion by 2030. The biologic drugs segment represents a tremendous opportunity for our Company, combining our pharma-grade, regulator-approved manufacturing infrastructure and our deep knowledge and expertise in the pharma industry.
https://legacy.pluristem.com/wp-content/uploads/2022/09/Pluri_-_CEO_Letter_FINAL_FOR_RELEASE_isa.pdf
Tweet Tweet
Come meet Pluri's VP Business Development Efrat Kaduri at Bio Europe, between Oct 24-26: https://t.co/fbTIgb49HR#innovation #celltherapy #biotechnology #bioeurope pic.twitter.com/Rvs1PO1Z9e
— Pluri (@Pluribiotech) October 24, 2022
Final HipGen Meeting Video.
Bio-Europe Next Week !!!
https://legacy.pluristem.com/events/
Upcoming Events
https://legacy.pluristem.com/events/
The Notice has no effect on the listing of the Company’s common shares at this time, and the Company’s common shares continue to trade on the Nasdaq Global Market under the symbol “PLUR.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1158780/000121390022063839/ea167091-8k_pluriinc.htm
FDA Clears Pluri Radiation Treatment For Emergency Use
https://www.reuters.com/article/us-pluristem-stem-cell-radiation/fda-clears-pluristem-radiation-treatment-for-emergency-use-idUSKBN1I10Y3
PLX-R18
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia.
PLX-R18 demonstrated positive results in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and it is in development to treat Acute Radiation Syndrome (ARS).
PLX-R18 cell therapy was granted an orphan drug designation by the FDA for the treatment of graft failure, incomplete hematopoietic recovery following HCT and ARS. The Orphan Drug Act provides for granting special status to a drug or biological product, to treat a rare disease or condition. The benefits of achieving Orphan Drug Designation include close guidance by the FDA, which may accelerate the path to potential marketing approval, orphan drug grants, tax credits, and 7-year market exclusivity upon marketing approval.
The FDA has also cleared Pluristem’s Investigational New Drug (IND) application for PLX-R18 in the treatment of ARS. The IND allows Pluristem to treat victims who may have been acutely exposed to high dose radiation due to nuclear attack or accident.
PLX-R18 is also being evaluated in preclinical studies to explore its therapeutic potential to treat a variety of other hematologic indications.
Read more about PLX-R18 in the treatment of Bone Marrow Deficiencies and ARS – Acute Radiation Syndrome.
A PLURI Article Came Out In The Jerusalem Post Today !!! IMO...The US Government Now Realizes It Should Have Ordered PLX-R18 Years Ago. My Gut Tells Me It's Going To Get FDA Approval Very Soon.... So It Can Be Manufactured On A Large Scale For The Government Stockpile !!! GIDDY-UP !!!
https://www.msn.com/en-ca/health/medical/if-putin-uses-nuclear-weapons-how-can-we-treat-radiation-poisoning/ar-AA12L4Gi
TASE Is Closed Tuesday & Wednesday This Week.
Leading European Manufacturer of Active Pharmaceutical Ingredients (APIs) to use Pluri’s 3D cell expansion technology, which aims to revolutionize the production of biologics by enabling cost effective, sustainable, and cruelty-free ingredients
Our cell expansion platform could prove to be a game-changer in the production of biologics, enabling cost-effective, sustainable, and cruelty-free ingredients. Biologic medications, made from live organisms, comprise a rapidly growing industry valued at $366 billion in 2021 and projected to grow to $720 billion by 2030. The biologic drugs segment represents a tremendous opportunity for our Company, combining our pharma-grade, regulator-approved manufacturing infrastructure and our deep knowledge and expertise in the pharma industry.
We believe that proof of concept with this agreement and APIs will open opportunities for us to serve additional API manufacturers in the rapidly
growing, multi-billion-dollar biologics market. As part of our collaboration with this major European company, our platform is being utilized to develop and manufacture a unique biologic API used in drugs that treat liver and gastroenterological diseases.
API Collaboration Signed
I am pleased to announce an additional technology collaboration, this time in the biologics industry. Due to a confidentiality agreement with our partner, I can only share limited details at this stage, and we will provide more information once we are able to do so.We have entered a collaboration agreement with one of the world’s leading manufacturers of specialty biologic APIs for liver and gastroenterological diseases. We believe that proof of concept with this agreement and APIs will open opportunities for us to serve additional API manufacturers in the rapidly growing, multi-billion-dollar biologics market. As part of our collaboration with this major European company, our platform is being utilized to develop and manufacture a unique biologic API used in drugs that treat liver and gastroenterological diseases
https://legacy.pluristem.com/wp-content/uploads/2022/09/Pluri_-_CEO_Letter_FINAL_FOR_RELEASE_isa.pdf
Note The Heading In Red !!!
https://informaconnect.com/cell-therapy-bioprocessing/agenda/2/
Wednesday, September 28th
https://informaconnect.com/cell-therapy-bioprocessing/speakers/lior-raviv-1/
IMO...They Are Coming Soon ????
We believe that we have sufficient cash to fund our operations for at least the next twelve months. On June 30, 2022, we had a working capital surplus of $50,918,000
During the year ended June 30, 2022, we did not sell of our any common shares under the ATM Agreement.
We expect to generate revenues, from the sale of licenses to use our technology or products, but in the short and medium terms will unlikely exceed our costs of operations.
As of June 30, 2022, the Company’s cash position (cash and cash equivalents, short-term bank deposits, long-term bank deposits, restricted cash and restricted bank deposits) totaled $56,657. The Company plans to continue to finance its operations from its current resources, by entering into licensing or other commercial agreements,
Cash and cash equivalents
Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less at the date acquired.
News Coming !!!
For Mr. Yanay and Ms. Franco-Yehuda, we have accrued, but have not yet paid, bonuses during Fiscal Year 2022 of $64,000 and $44,000 respectively, for certain target bonuses as a result of the achievement of certain milestones that were defined by the Compensation Committee. We expect to pay such bonuses during October 2022.
September Company Presentation Posted Today
https://legacy.pluristem.com/presentations/
Biden’s Biotech Moonshot Lights the Way for Regulatory Approval of Cultivated Meat
https://www.greenqueen.com.hk/bidens-biotech-moonshot-regulatory-approval-of-cultivated-meat/
Biden Backs Lab Grown Meat
https://www.newsweek.com/lab-grown-meat-invested-biden-government-1742816
10K Due Out After The Bell On Tuesday.
Tweet Tweet....7:00 AM Monday Morning !!!
https://twitter.com/Pluribiotech
Tweet Tweet
Wink Wink ???
https://twitter.com/Pluribiotech
They Are Completely Oblivious To What's Coming !!!
€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment
https://legacy.pluristem.com/wp-content/uploads/2022/09/PLUR_PROTO_Grant_FINAL_FOR_RELEASE_isa.pdf
Pluri: Where Technology Comes To Life
Last Paragraph Is Very Interesting !!!
“Another issue that has been gaining focus in the past year is marine life and the massive destruction of marine ecosystems, which affects us in an extreme way. There, too, we can contribute. Our technology makes it possible to produce rare, hard-to-obtain components that can have a significant impact on the environment.”
https://www.jpost.com/business-and-innovation/tech-and-start-ups/article-716164
Sweet Tweet !!!
https://twitter.com/Pluribiotech